Progyny (NASDAQ:PGNY) Issues Q1 2025 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.440-0.470 for the period, compared to the consensus earnings per share estimate of 0.400. The company issued revenue guidance of $300.0 million-$318.0 million, compared to the consensus revenue estimate of $280.5 million. Progyny also updated its FY 2025 guidance to 1.520-1.620 EPS.

Progyny Trading Down 0.5 %

Shares of PGNY stock opened at $22.88 on Friday. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of 39.45, a PEG ratio of 2.39 and a beta of 1.34. The firm’s 50 day moving average is $20.52 and its 200-day moving average is $18.68. Progyny has a 1 year low of $13.39 and a 1 year high of $38.98.

Analyst Ratings Changes

Several equities analysts recently weighed in on PGNY shares. Canaccord Genuity Group cut their price objective on shares of Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a report on Wednesday, November 13th. Barclays dropped their price objective on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Bank of America raised their target price on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. upped their price target on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Finally, Truist Financial reissued a “hold” rating and set a $19.00 price objective (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $25.83.

Insiders Place Their Bets

In related news, Chairman David J. Schlanger bought 150,000 shares of Progyny stock in a transaction that occurred on Thursday, December 26th. The stock was acquired at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now owns 228,269 shares of the company’s stock, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the purchase, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. The trade was a 90.32 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.